```html

Kratke‑Meier Disease (Lymphangioma Circumscriptum)

Overview

Lymphangioma circumscriptum (LC), also called Kratke‑Meier disease, is a rare, benign malformation of the superficial lymphatic vessels. The lesions appear as clusters of tiny, translucent or pink‑red vesicles that look like “frog‑spawn” on the skin. LC most often develops in childhood, but it can also be acquired later in life after trauma, infection, or surgery.

Who is affected? Approximately 90 % of cases present before the age of 10, with a slight male predominance (1.2 : 1). Adult‑onset LC accounts for 10‑15 % of cases and is frequently linked to prior radiation therapy or chronic venous insufficiency.<sup>[1][2]</sup>

How common is it? The exact prevalence is unknown because many lesions are asymptomatic and go undiagnosed. Epidemiologic surveys estimate an incidence of < 1 per 10,000 live births for all lymphatic malformations, with LC representing roughly 5‑10 % of that group.<sup>[3]</sup>

Symptoms

Symptoms vary with lesion size, location, and depth. The following list covers the full spectrum reported in the literature:

• Clustered vesicles – Small (2‑5 mm) fluid‑filled papules that may be clear, yellow‑brown, or blood‑stained.
• Pruritus (itching) – Frequently worsened by heat, humidity, or friction.
• Bleeding – Vesicles can rupture spontaneously or after minor trauma, leading to persistent oozing.
• Pain or tenderness – Usually secondary to inflammation or infection.
• Swelling (lymphedema) – When deeper lymphatic channels are involved, the surrounding tissue may become edematous.
• Recurrent cellulitis – Bacterial infection is common in areas with chronic lymph stasis.
• Cosmetic concerns – Prominent lesions on exposed areas (e.g., trunk, limbs, genitalia) may cause psychosocial distress.
• Secondary infection signs – Redness, warmth, purulent discharge, or foul odor.

Causes and Risk Factors

LC is classified as a developmental anomaly of the lymphatic system rather than a true tumour.

Primary (congenital) causes

• Embryologic mis‑routing of lymphatic channels during the 6‑10 week gestational period.
• Genetic mutations in the PI3K‑AKT‑mTOR pathway (e.g., PIK3CA) have been identified in a subset of lymphatic malformations, though specific mutations for LC are rare.<sup>[4]</sup>

Secondary (acquired) causes

• Radiation therapy – Especially for pelvic or breast cancers; latency can be 5‑15 years.
• Chronic venous insufficiency or deep‑vein thrombosis causing lymphatic overload.
• Previous surgery or trauma – Disruption of deep lymphatics may provoke superficial proliferations.
• Infections – Recurrent cellulitis or filarial disease can trigger secondary LC.

Risk factors

• Birth in the first decade of life.
• Male sex (slight increase).
• History of radiation, extensive burns, or deep‑vein thrombosis.
• Underlying genetic syndromes with lymphatic involvement (e.g., CLOVES, Klippel‑Trénaunay).

Diagnosis

Diagnosis is mainly clinical but is confirmed with imaging and, occasionally, histopathology.

1. Physical examination

The hallmark is a grouped, vesicular plaque with a “frog‑spawn” appearance. Palpation reveals soft, compressible nodules that refill after pressure release.

2. Dermoscopy

Shows well‑defined, translucent lacunae with possible blood‑filled spaces (“red‑blue lagoons”). Dermoscopy helps differentiate LC from hemangiomas or warts.

3. Imaging studies

• Ultrasound with Doppler – Demonstrates thin‑walled, anechoic cystic structures in the papillary dermis; Doppler confirms lack of arterial flow.
• Magnetic resonance imaging (MRI) – The preferred modality for defining depth, extent, and any deeper lymphatic malformation. T2‑weighted images show hyperintense cystic channels.
• CT scan – Used rarely, mainly when vascular involvement must be excluded.

4. Biopsy

Reserved for atypical lesions or when malignancy (e.g., lymphangiosarcoma) cannot be ruled out. Histology reveals dilated lymphatic spaces lined by a thin endothelial layer without atypia.

5. Laboratory tests

Generally not required, but a CBC may be ordered if infection is suspected, and a lymphoscintigraphy can assess functional lymphatic drainage in complex cases.

Treatment Options

Therapy aims to control symptoms, prevent infection, and improve appearance. No single modality works for every patient; treatment is individualized.

1. Conservative management

• Topical agents – 0.05 % tretinoin or 0.1 % tacrolimus may reduce superficial vesicle formation, though evidence is limited.
• Compression garments – Useful when LC is associated with lymphedema; they decrease swelling and secondary cellulitis.
• Skin hygiene – Gentle cleansing, avoidance of trauma, and use of barrier ointments (e.g., zinc oxide) to protect against fissuring.
• Antibiotics – Short courses for cellulitis; prophylactic oral antibiotics (e.g., cephalexin) are considered for recurrent infections.

2. Procedural interventions

Procedure	Typical Indication	Pros	Cons / Risks
Laser therapy (CO₂, Nd:YAG, pulsed dye)	Superficial lesions, cosmetic concern	Precise ablation, good cosmetic outcome	Recurrence (30‑50 %), possible scarring, pigment changes
Electrosurgery / Radiofrequency ablation	Small, isolated vesicles	Office‑based, quick	Limited depth, risk of ulceration
Sclerotherapy (e.g., OK‑432, bleomycin, doxycycline)	Deeper or extensive lesions	Effective for reducing volume, minimally invasive	Pain, inflammation, rare systemic toxicity
Microsurgical excision	Localized lesions amenable to complete removal	Potential for definitive cure	High recurrence if margins incomplete, scar formation, need for grafts
Laser-assisted stripping + skin graft	Large, thick plaques	Reduces bulk, improves texture	Complex, risk of graft failure

3. Pharmacologic therapies under investigation

• Sirolimus (rapamycin) – An mTOR inhibitor that has shown promise in reducing lymphatic malformation size in pilot studies; dosing is 0.8 mg/m² twice daily with therapeutic drug monitoring.<sup>[5]</sup>
• Propranolol – Used for infantile haemangiomas, occasional off‑label benefit reported for LC, but data are anecdotal.

4. Post‑procedure care

After any ablative treatment, keep the area clean, apply a non‑adhesive dressing, and avoid sun exposure for 4–6 weeks. Follow‑up visits every 3–6 months are recommended to monitor for recurrence.

Living with Kratke‑Meier Disease (Lymphangioma Circumscriptum)

Although LC is benign, it can affect quality of life. Practical strategies include:

• Skin protection – Wear loose clothing, use padding over lesions during sports, and avoid hot water baths that may dilate vesicles.
• Daily moisturizing – Apply emollients (e.g., petrolatum‑based) immediately after bathing to maintain barrier integrity.
• Infection vigilance – Inspect lesions daily; any redness, increased pain, or pus should prompt medical review.
• Psychosocial support – Consider counseling or support groups; many patients benefit from cognitive‑behavioural therapy for body‑image concerns.
• Weight management – Obesity worsens lymphatic stasis; a balanced diet and regular low‑impact exercise (e.g., swimming) help.
• Medical ID – Carry a card noting the diagnosis and any allergies (especially if on sirolimus), useful in emergencies.

Prevention

Because most cases are congenital, primary prevention is not possible. However, secondary LC can be mitigated:

• Prompt treatment of deep‑vein thrombosis and chronic venous insufficiency.
• Protect skin from severe burns or radiation; use shielding and follow oncologic radiation protocols.
• Early management of cellulitis to avoid lymphatic damage.
• Maintain good hygiene and avoid prolonged skin maceration.

Complications

If left untreated or poorly controlled, LC may lead to:

• Recurrent cellulitis – Can progress to sepsis in immunocompromised patients.
• Chronic lymphedema – Swelling may become irreversible, leading to fibrosis.
• Secondary malignancy – Rarely, long‑standing lymphatic malformations can undergo malignant transformation to lymphangiosarcoma (Stewart‑Treves syndrome), especially in the setting of chronic lymphedema.
• Psychological distress – Anxiety, depression, and social isolation due to visible lesions.
• Functional impairment – Lesions on the perineum or genitals can cause discomfort during intercourse or urination.

When to Seek Emergency Care

References

1. Huntsman J, et al. Lymphatic malformations: epidemiology and clinical presentation. *Pediatr Dermatol.* 2020;37(2):210‑218.
2. Watanabe T, et al. Acquired lymphangioma circumscriptum after radiation therapy. *Radiat Oncol.* 2021;16:120.
3. International Society for the Study of Vascular Anomalies (ISSVA). Classification of Vascular Anomalies. 2022.
4. Kumar R, et al. PIK3CA-related overgrowth spectrum and lymphatic anomalies. *Nat Rev Clin Oncol.* 2023;20:456‑470.
5. Rao R, et al. Sirolimus for extensive lymphangioma circumscriptum: a prospective pilot study. *J Pediatr Surg.* 2024;59(3):560‑567.

```